Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1

Journal of Physiology and Pharmacology

Volumn 61, Issue 3, 2010, Pages 287-294

  Yoda, Y ^a   Amagase, K ^b   Kato, S ^b   Tokioka, S ^a   Murano, M ^a   Kakimoto, K ^a   Nishio, H ^b   Umegaki, E ^a   Takeuchi, K ^b   Higuchi, K ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Carbon oxide; Heme oxygenase 1; Indomethacin; Intestinal lesions; Lansoprazole; Nitric oxide; Nonsteroidal anti inflammatory drugs

Indexed keywords

CARBON MONOXIDE; CARBON MONOXIDE RELEASING MOLECULE 2; HEME OXYGENASE 1; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LANSOPRAZOLE; MESSENGER RNA; MYELOPEROXIDASE; OMEPRAZOLE; PROTOPORPHYRIN TIN; UNCLASSIFIED DRUG; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; HEME OXYGENASE; HMOX1 PROTEIN, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOMETALLIC COMPOUND; PEROXIDASE; PROTON PUMP INHIBITOR; TRICARBONYLDICHLORORUTHENIUM (II) DIMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENTEROBACTERIACEAE; ENZYME INDUCTION; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INTESTINE ULCER; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE MUCOSA; SPECIES INVASION; UPREGULATION; ANIMAL; BACTERIAL COUNT; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INTESTINAL DISEASES; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; SMALL INTESTINE; SPRAGUE DAWLEY RAT; TOXICITY; ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONY COUNT, MICROBIAL; ENTEROBACTERIACEAE; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; INDOMETHACIN; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINE, SMALL; LANSOPRAZOLE; MALE; NITRIC OXIDE SYNTHASE TYPE II; ORGANOMETALLIC COMPOUNDS; PEROXIDASE; PROTON PUMP INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ULCER;

EID: 77957063789     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Robert A, Asano T. Resistance of germ-free rats to indomethacin-induced intestinal inflammation. Prostaglandins 1977; 14: 333-341.
2. Fang WF, Broughton A, Jacobson ED. Indomethacin induced intestinal inflammation. Am J Dig Dis 1977; 22: 749-760.
3. Goldstein JL, Eisen GM, Lewis B, Granlnek IM, Zlontnick S, Fort JG. Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141.
4. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178.
5. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59.
6. Sugimori S, Watanabe T, Tabuchi M, et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008; 78: 208-213.
7. Whittle BJ. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981; 80: 94-98.
8. Whittle BJR, Laszlo F, Evans SM, Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol 1994; 116: 2286-2290.
9. Weissenborn U, Maedge S, Buettner D, Sewing KF. Indomethacin-increased gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 1985; 30: 32-39.
10. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-662.
11. Konaka A, Tanaka A, Kato S, Nishijima M, Takeuchi K. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced intestinal lesions in rats. J Pharmacol Physiol 1999; 50: 25-38.
12. Tanaka A, Kunikata T, Mizoguchi H, Kato S, Takeuchi K. Dual action of nitric oxide in pathogenesis of indomethacininduced small intestinal ulceration in rats. J Physiol Pharmacol 1999; 50: 405-417.
13. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002; 66: 30-41.
14. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Tolllike receptor 4 dependent. Gut 2008; 57: 181-187.
15. Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6: 1279-1282.
16. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. Thepharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
17. Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-esophageal reflux disease and peptic ulcers impaired by non-steroidal anti-inflammatory drugs. Drugs 1998; 56: 447-486.
18. Kobayashi T, Ohta Y, Inui K, Yoshino J, Nakazawa S. Protective effect of omeprazole against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats. Pharmacol Res 2002; 46: 75-84.
19. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. Anovel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003; 278: 10993-11001.
20. Natale G, Lazzeri G, Lubrano V, et al. Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. Toxicol Appl Pharmacol 2004; 195: 1710-1715.
21. Fornai M, Natale G, Colucci R, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 2005; 372: 79-87.
22. Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol 2004; 10: 2814-2817.
23. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacininduced rat enteritis. Int J Mol Med 2006; 17: 89-93.
24. Pozzoli C, Menozzi A, Grandi D, et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn-Schmiedebergs Arch Pharmacol 2007; 374: 283-291.
25. Sikora A, Grzesiuk E. Heat shock response in gastrointestinal tract. J Physiol Pharmacol 2007; 58(Suppl 3): 43-62.
26. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-554.
27. Wang WP, Guo X, Koo MWL, et al. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am J Physiol 2001; 281: G586-G594.
28. Becker JC, Grosser N, Boknik P, Schroder H, Domschke W, Pohle T. Gastroprotection by vitamin C - a heme oxygenase-1-dependent mechanism? Biochem Biophys Res Commnun 2003; 312: 507-512.
29. Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: Proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006; 345: 1014-1021.
30. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002; 303: 1248-1254.
31. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-1350.
32. Kato S, Tanaka A, Kunikata T, Umeda M. Takeuchi K. Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: Relation to capsaicin-sensitive sensory neurons. Digestion 2000; 61: 39-46.
33. Taha H, Grochot-Przeczek A, Was H, et al. Modulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathway. J Physiol Pharmacol 2009; 60: 3-12.
34. Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, Ichinose M. Polaprezinc (Zinc L-carnosine) is a potent inducer of antioxidative stress enzyme, heme oxygenase (HO)-1 - a new mechanism of gastric mucosal protection. J Pharmacol Sci 2009; 110: 285-294.
35. Takagi T, Naito Y, Okada H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 2009; 331: 255-264.
36. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-755.
37. Otterbein LE, Mantell LL, Cho AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999; 276: L688-L694.
38. Sato K, Balla J, Otterbein L, et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol 2001; 166: 4185-4194.
39. Morisaki H, Katayama T, Kotake Y, et al. Carbon monoxide modulates endotoxin-induced micoravascular leukocyte adhesion through platelet-dependent mechanisms. Anesthesiology 2002; 97: 701-709.
40. Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr Pharm 2003; 9: 2525-2539.
41. Vera T, Henegar JR, Drummond HA, Rimoldi JM, Stec DE. Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J Am Soc Nephrol 2005; 16: 950-958.
42. Takeuchi K, Yokota A, Taniguchi M, Takahira Y, Tanaka A. Factors involved in up-regulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal antiinflammatory drugs. Dig Dis Sci 2006; 51: 1250-1259.
43. Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R. Carbon monoxide-releasing molecules (CORMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br J Pharmacol 2005; 145: 800-810.
44. Bani-Hani MG, Greenstein D, Mann BE, Green CJ, Motterlini R. Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxidereleasing molecule 3. J Pharmacol Exp Ther 2006; 318: 1315-1322.
45. Dijkstra G, Blokzil H, Homan M, et al. Opposite effect of oxidative stress on inducible nitric oxide synthase and heme oxygenase-1 expression in intestinal inflammation: anti-inflammatory effect of carbon monoxide. J Pathol 2004; 204: 296-303.
46. Minamoto K, Harada H, Lama VN, Fedarau MA, Pinsky DJ. Reciprocal regulation airway rejection by the inducible gasforming enzymes heme oxygenase and nitric oxide synthase. J Exp Med 2005; 202: 283-294.
47. Megias J, Busserolles J, Alcaraz MJ. The carbon monoxidereleasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. Br J Pharmacol 2007; 150: 977-986.
48. Kato S, Nishio H, Ogura M, Takeuchi K. Tacrolimus (FK506), an immunosuppressive agent, prevents indomethacin-induced small intestinal ulceration in the rat: inhibition of inducible nitric oxide synthase expression. J Pharmacol Sci 2007; 103: 40-47.
49. Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, Takeuchi K. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 2008; 53: 2657-2666.